Cantor Fitzgerald Estimates Annexon FY2025 Earnings

Annexon, Inc. (NASDAQ:ANNXFree Report) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Annexon in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($0.99) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

ANNX has been the topic of several other reports. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Annexon in a report on Tuesday, December 17th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $15.80.

Read Our Latest Report on ANNX

Annexon Stock Performance

Shares of NASDAQ ANNX opened at $4.15 on Wednesday. Annexon has a 1 year low of $3.86 and a 1 year high of $8.40. The company’s fifty day moving average price is $5.03 and its 200 day moving average price is $5.91. The company has a market capitalization of $442.35 million, a PE ratio of -3.95 and a beta of 1.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. lifted its position in shares of Annexon by 65.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 429,584 shares of the company’s stock valued at $2,204,000 after acquiring an additional 170,180 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Annexon by 16.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock valued at $10,101,000 after purchasing an additional 235,810 shares during the last quarter. Franklin Resources Inc. purchased a new position in Annexon in the 3rd quarter valued at $292,000. Barclays PLC boosted its stake in Annexon by 212.0% during the 3rd quarter. Barclays PLC now owns 177,765 shares of the company’s stock worth $1,052,000 after purchasing an additional 120,789 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Annexon by 18.3% during the third quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after buying an additional 331,269 shares in the last quarter.

Annexon Company Profile

(Get Free Report)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

See Also

Earnings History and Estimates for Annexon (NASDAQ:ANNX)

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.